Toward Precision Adjuvants: Optimizing Science and Safety

Overview

Journal Curr Opin Pediatr

Specialty Pediatrics

Date 2020 Jan 7

PMID 31904601

Citations 57

Authors

Etsuro Nanishi

David J Dowling

Ofer Levy

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The gradual replacement of inactivated whole cell and live attenuated vaccines with subunit vaccines has generally reduced reactogenicity but in many cases also immunogenicity. Although only used when necessary, adjuvants can be key to vaccine dose/antigen-sparing, broadening immune responses to variable antigens, and enhancing immunogenicity in vulnerable populations with distinct immunity. Licensed vaccines contain an increasing variety of adjuvants, with a growing pipeline of adjuvanted vaccines under development.

Recent Findings: Most adjuvants, including Alum, Toll-like receptor agonists and oil-in-water emulsions, activate innate immunity thereby altering the quantity and quality of an adaptive immune response. Adjuvants activate leukocytes, and induce mediators (e.g., cytokines, chemokines, and prostaglandin-E2) some of which are biomarkers for reactogenicity, that is, induction of local/systemic side effects. Although there have been safety concerns regarding a hypothetical risk of adjuvants inducing auto-immunity, such associations have not been established. As immune responses vary by population (e.g., age and sex), adjuvant research now incorporates principles of precision medicine. Innovations in adjuvant research include use of human in vitro models, immuno-engineering, novel delivery systems, and systems biology to identify biomarkers of safety and adjuvanticity.

Summary: Adjuvants enhance vaccine immunogenicity and can be associated with reactogenicity. Novel multidisciplinary approaches hold promise to accelerate and de-risk targeted adjuvant discovery and development. VIDEO ABSTRACT: http://links.lww.com/MOP/A53.

Citing Articles

A synthetic cyclic peptide for promoting antigen presentation and immune activation.

Zhang J, Madge H, Mahmoud A, Lu L, Wang W, Huang W NPJ Vaccines. 2025; 10(1):9.

PMID: 39809901 PMC: 11733015. DOI: 10.1038/s41541-024-01050-4.

Role of Adjuvants in Enhancing the Efficacy and Duration of Anesthesia Blocks: A Comprehensive Review.

Singhal A, Taksande K Cureus. 2024; 16(9):e69880.

PMID: 39439610 PMC: 11494027. DOI: 10.7759/cureus.69880.

Transforming vaccinology.

Rappuoli R, Alter G, Pulendran B Cell. 2024; 187(19):5171-5194.

PMID: 39303685 PMC: 11736809. DOI: 10.1016/j.cell.2024.07.021.

From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation.

Soni D, Borriello F, Scott D, Feru F, DeLeon M, Brightman S Sci Adv. 2024; 10(27):eadg3747.

PMID: 38959314 PMC: 11221515. DOI: 10.1126/sciadv.adg3747.

Immune profiling of age and adjuvant-specific activation of human blood mononuclear cells in vitro.

Schuller S, Barman S, Mendez-Giraldez R, Soni D, Daley J, Baden L Commun Biol. 2024; 7(1):709.

PMID: 38851856 PMC: 11162429. DOI: 10.1038/s42003-024-06390-4.

References

Ghosh T, Mickelson D, Solberg J, Lipson K, Inglefield J, Alkan S . TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha. Int Immunopharmacol. 2007; 7(8):1111-21. DOI: 10.1016/j.intimp.2007.04.006. View

Kollmann T, Kampmann B, Mazmanian S, Marchant A, Levy O . Protecting the Newborn and Young Infant from Infectious Diseases: Lessons from Immune Ontogeny. Immunity. 2017; 46(3):350-363. DOI: 10.1016/j.immuni.2017.03.009. View

Di Pasquale A, Preiss S, Da Silva F, Garcon N . Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines (Basel). 2015; 3(2):320-43. PMC: 4494348. DOI: 10.3390/vaccines3020320. View

Cunningham A, Lal H, Kovac M, Chlibek R, Hwang S, Diez-Domingo J . Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016; 375(11):1019-32. DOI: 10.1056/NEJMoa1603800. View

Nolan T, Roy-Ghanta S, Montellano M, Weckx L, Ulloa-Gutierrez R, Lazcano-Ponce E . Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. J Infect Dis. 2014; 210(4):545-57. PMC: 4111912. DOI: 10.1093/infdis/jiu173. View

Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C . Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A. 2008; 105(30):10501-6. PMC: 2483233. DOI: 10.1073/pnas.0804699105. View

Burns Jr R, FERBEL B, Tomai M, Miller R, Gaspari A . The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol. 1999; 94(1):13-23. DOI: 10.1006/clim.1999.4804. View

Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A . Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature. 1984; 308(5958):457-60. DOI: 10.1038/308457a0. View

Tom J, Albin T, Manna S, Moser B, Steinhardt R, Esser-Kahn A . Applications of Immunomodulatory Immune Synergies to Adjuvant Discovery and Vaccine Development. Trends Biotechnol. 2018; 37(4):373-388. DOI: 10.1016/j.tibtech.2018.10.004. View

10.

Agnandji S, Lell B, Fernandes J, Abossolo B, Methogo B, Lumeka Kabwende A . A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012; 367(24):2284-95. PMC: 10915853. DOI: 10.1056/NEJMoa1208394. View

11.

Philbin V, Dowling D, Gallington L, Cortes G, Tan Z, Suter E . Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. J Allergy Clin Immunol. 2012; 130(1):195-204.e9. PMC: 3387351. DOI: 10.1016/j.jaci.2012.02.042. View

12.

Bottazzi B, Santini L, Savino S, Giuliani M, Duenas Diez A, Mancuso G . Recognition of Neisseria meningitidis by the long pentraxin PTX3 and its role as an endogenous adjuvant. PLoS One. 2015; 10(3):e0120807. PMC: 4364741. DOI: 10.1371/journal.pone.0120807. View

13.

Levy O, Zarember K, Roy R, Cywes C, Godowski P, Wessels M . Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J Immunol. 2004; 173(7):4627-34. DOI: 10.4049/jimmunol.173.7.4627. View

14.

Destexhe E, Prinsen M, van Scholl I, Kuper C, Garcon N, Veenstra S . Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for vaccine nonclinical safety studies. J Pharmacol Toxicol Methods. 2013; 68(3):367-73. DOI: 10.1016/j.vascn.2013.04.003. View

15.

Netea M, Schlitzer A, Placek K, Joosten L, Schultze J . Innate and Adaptive Immune Memory: an Evolutionary Continuum in the Host's Response to Pathogens. Cell Host Microbe. 2019; 25(1):13-26. DOI: 10.1016/j.chom.2018.12.006. View

16.

Lovgren Bengtsson K, Morein B, Osterhaus A . ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines. 2011; 10(4):401-3. DOI: 10.1586/erv.11.25. View

17.

Del Giudice G, Rappuoli R, Didierlaurent A . Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol. 2018; 39:14-21. DOI: 10.1016/j.smim.2018.05.001. View

18.

Dowling D, Sanders H, Cheng W, Joshi S, Brightman S, Bergelson I . A Meningococcal Outer Membrane Vesicle Vaccine Incorporating Genetically Attenuated Endotoxin Dissociates Inflammation from Immunogenicity. Front Immunol. 2016; 7:562. PMC: 5143884. DOI: 10.3389/fimmu.2016.00562. View

19.

Bjork Wilhelms D, Kirilov M, Mirrasekhian E, Eskilsson A, Ortegren Kugelberg U, Klar C . Deletion of prostaglandin E2 synthesizing enzymes in brain endothelial cells attenuates inflammatory fever. J Neurosci. 2014; 34(35):11684-90. PMC: 6608410. DOI: 10.1523/JNEUROSCI.1838-14.2014. View

20.

Phillips B, Van Rompay K, Rodriguez-Nieves J, Lorin C, Koutsoukos M, Tomai M . Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. J Virol. 2018; 92(20). PMC: 6158427. DOI: 10.1128/JVI.01051-18. View